Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Focal Segmental Glomerulosclerosis Clinical Trial
NCT00135811Phase 3Completed
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases
- Start
- Nov 2004
- Primary completion
- Nov 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of mycophenolate mofetil in focal segmental glomerulosclerosis (FSGS) (2 arms), sponsored by National Institute of Diabetes and Digestive and Kidney Diseases. Primary endpoint: Partial or Complete Proteinuria Remission at 52 weeks. Started Nov 2004; status: completed.
02
Drugs
mycophenolate mofetil
03
Conditions
focal segmental glomerulosclerosis (FSGS)
Beyond the preview
Go deeper on NCT00135811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00135811.